InspireMD will announce Q2 2025 financial results on August 5, 2025, with a conference call at 8:30 a.m. ET.
Quiver AI Summary
InspireMD, Inc. announced that it will release its second quarter 2025 financial results on August 5, 2025. The company, known for its CGuard® Prime carotid stent system, will hold a conference call and webcast at 8:30 a.m. Eastern Time to discuss the results and recent developments. Interested participants can join the call by dialing specified numbers for domestic and international listeners or by accessing the webcast on the company's website. A replay of the webinar will be made available shortly after the call. InspireMD aims to set a new industry standard in carotid stenting using its MicroNet™ mesh technology.
Potential Positives
- InspireMD is set to announce its second quarter 2025 financial results, which could provide insights into the company's performance and growth potential.
- The company is hosting a conference call and webcast to discuss financial results and highlights, fostering transparency and engagement with investors.
- InspireMD emphasizes its commitment to utilizing proprietary technology to establish a standard for carotid stenting, which may enhance its competitive position in the market.
- The announcement indicates ongoing communication efforts by InspireMD to keep investors informed, reinforcing investor relations and trust.
Potential Negatives
- None
FAQ
When will InspireMD release its second quarter 2025 financial results?
InspireMD will release its second quarter 2025 financial results on Tuesday, August 5, 2025.
What time is the InspireMD conference call scheduled?
The conference call is scheduled for 8:30 a.m. Eastern Time on August 5, 2025.
How can I access InspireMD's earnings conference call?
You can access the call by dialing 1-800-579-2543 for domestic callers or 1-785-424-1789 for international callers.
Where can I find the replay of the InspireMD webcast?
A replay of the webcast will be available on InspireMD’s website shortly after the call concludes.
What is the main focus of InspireMD's technology?
InspireMD focuses on utilizing its MicroNet™ mesh technology for carotid stenting, aiming for outstanding acute and long-term outcomes.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$NSPR Hedge Fund Activity
We have seen 11 institutional investors add shares of $NSPR stock to their portfolio, and 6 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- NANTAHALA CAPITAL MANAGEMENT, LLC added 643,452 shares (+38.4%) to their portfolio in Q1 2025, for an estimated $1,730,885
- SOLEUS CAPITAL MANAGEMENT, L.P. removed 432,752 shares (-31.4%) from their portfolio in Q1 2025, for an estimated $1,164,102
- PARKMAN HEALTHCARE PARTNERS LLC added 316,700 shares (+37.1%) to their portfolio in Q1 2025, for an estimated $851,923
- MILLENNIUM MANAGEMENT LLC removed 313,981 shares (-94.9%) from their portfolio in Q1 2025, for an estimated $844,608
- ROSALIND ADVISORS, INC. removed 220,793 shares (-8.8%) from their portfolio in Q1 2025, for an estimated $593,933
- MORGAN STANLEY removed 53,035 shares (-42.7%) from their portfolio in Q1 2025, for an estimated $142,664
- RAYMOND JAMES FINANCIAL INC added 34,604 shares (+inf%) to their portfolio in Q1 2025, for an estimated $93,084
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$NSPR Analyst Ratings
Wall Street analysts have issued reports on $NSPR in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Piper Sandler issued a "Overweight" rating on 05/12/2025
To track analyst ratings and price targets for $NSPR, check out Quiver Quantitative's $NSPR forecast page.
Full Release
MIAMI, Fla., July 22, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard ® Prime carotid stent system for the prevention of stroke, today announced that it will release its second quarter 2025 financial results on Tuesday, August 5, 2025. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights.
Interested parties may access the live earnings call via telephone by dialing 1-800-579-2543 for domestic callers or 1-785-424-1789 for international callers. The live webinar may be accessed by visiting InspireMD’s website or by registering below. A replay of the webinar will be available shortly after the conclusion of the call and will be archived on InspireMD’s website.
Webcast : https://viavid.webcasts.com/starthere.jsp?ei=1723041&tp_key=b02c396fff
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet™ mesh technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD’s common stock is quoted on Nasdaq under the ticker symbol NSPR.
We routinely post information that may be important to investors on our website. For more information, please visit www.inspiremd.com .
Investor Contact:
Webb Campbell
Gilmartin Group LLC
[email protected]
[email protected]
